The Department of Justice (DOJ)’s July 23, 2026, settlement with Magnolia Diagnostics is a notable reminder for investors in healthcare companies: distributions from a portfolio company may be subject to clawback when the government later alleges that the company’s revenues were generated through False Claims Act (FCA) violations.
FCA cases against investors in healthcare are not new. DOJ and the whistleblower bar pay close attention to healthcare companies following a change of control and often allege that investors caused the submission of false claims by actively managing the acquired company, imposing performance incentives, and placing an outsized focus on utilization and profit growth. The Magnolia settlement is different.
DOJ did not pursue the investors under the FCA. Instead, it proceeded under the FDCPA, which allows the government to claw back distributions made by a debtor to the United States. The government’s theory was that Magnolia, while insolvent and indebted to the United States for its alleged Medicare overpayments, made distributions to its investors that threatened to frustrate the government’s ability to recoup those funds—a fraudulent-transfer theory distinct from, and independent of, direct FCA liability.
According to DOJ’s press release, Magnolia Diagnostics, a Dallas-based clinical laboratory, and its owners agreed to pay $19.2 million to resolve allegations that they violated the False Claims Act by billing Medicare for medically unnecessary...
U.S. Central Command (CENTCOM) said Monday that the Iranian Revolutionary Guard’s claim that a ship was struck by mines in the Strait of Hormuz was false, Ynet Global reported. CENTCOM wrote on X ...